Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1‐related breast carcinoma
Open Access
- 8 September 2003
- Vol. 98 (8) , 1569-1577
- https://doi.org/10.1002/cncr.11688
Abstract
BACKGROUND A positive correlation between breast tumor size and the number of axillary lymph nodes containing tumor is well established. It has been reported that patients with BRCA1‐related breast carcinoma are more likely than patients with nonhereditary breast carcinoma to have negative lymph node status. Therefore, the authors questioned whether the known positive correlation between tumor size and lymph node status also was present in women with BRCA1‐related breast carcinomas. METHODS The relation between the greatest dimension of the resected breast tumor (size) and the presence of positive axillary lymph nodes (expressed as a percentage of all lymph nodes examined) was evaluated in 1555 women with invasive breast carcinoma who were ascertained at 10 centers in North America between 1975 and 1997. There were 276 BRCA1 mutation carriers, 136 BRCA2 carriers, and 1143 women without a known mutation (208 BRCA1/BRCA2 noncarriers and 935 untested women). Patients were stratified according to tumor size, and odds ratios were estimated for the presence of positive lymph nodes with increasing tumor size. RESULTS A highly significant positive correlation between tumor size and the frequency of positive axillary lymph nodes was seen for BRCA1/BRCA2 noncarriers, for BRCA2 carriers, and for untested women (overall P < 0.0001 for each). In contrast, there was no clear correlation between tumor size and positive lymph node status in BRCA1 carriers (overall P = 0.20). CONCLUSIONS The relation between tumor size and lymph node status in patients with breast carcinoma appears to be different in BRCA1 carriers compared with BRCA2 carriers and noncarriers. These findings have important implications for estimating the route of metastatic spread and for evaluating the effectiveness of early diagnosis in patients with BRCA1‐related breast carcinoma. Cancer 2003. ©2003 American Cancer Society. DOI 10.1002/cncr.11688Keywords
Funding Information
- Canadian Genetic Diseases Network
- Susan G. Komen Foundation
- Fonds de la recherche en santé du Québec
- National Institutes of Health
This publication has 21 references indexed in Scilit:
- Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinomaCancer, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomyInternational Journal of Cancer, 2002
- Metastasis genes: A progression puzzleNature, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from FinlandInternational Journal of Cancer, 2001
- Gene-Expression Profiles in Hereditary Breast CancerNew England Journal of Medicine, 2001
- Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patientsNature Medicine, 1997
- Factors affecting the incidence of lymph node metastases in small cancers of the breastThe American Journal of Surgery, 1989